Kinetics of gadobenate dimeglumine in isolated perfused rat liver: MR imaging evaluation

Radiology

Volumn 229, Issue 1, 2003, Pages 119-125

  Pastor, Catherine M ^a   Planchamp, Corinne ^d   Pochon, Sibylle ^b   Lorusso, Vito ^c   Montet, Xavier ^a   Mayer, Joachim ^d   Terrier, François ^a   Vallée, Jean Paul ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b Bracco Suisse SA   (Switzerland)

^c Bracco SpA   (Italy)

^d NONE

Author keywords

Animals; Contrast media, experimental studies; Experimental study; Gadolinium; Liver, MR, Magnetic resonance, contrast media; Radiobiology, cell and tissue studies

Indexed keywords

BROMSULFOPHTHALEIN; GADOBENATE DIMEGLUMINE; GADOLINIUM PENTETATE; GADOLINIUM PENTETATE MEGLUMINE; ORGANIC ANION TRANSPORTER;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BILE DUCT LIGATION; BIOACCUMULATION; DRUG HALF LIFE; DRUG TRANSPORT; DRUG UPTAKE; EVALUATION; ISOLATED LIVER; KINETICS; LIVER CELL; LIVER PERFUSION; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RAT; STEADY STATE;

ANIMALS; BIOLOGICAL TRANSPORT; CONTRAST MEDIA; GADOLINIUM; GADOLINIUM DTPA; LIVER; MAGNETIC RESONANCE IMAGING; MALE; MEGLUMINE; ORGANOMETALLIC COMPOUNDS; OXYGEN CONSUMPTION; PORTAL PRESSURE; RATS; RATS, SPRAGUE-DAWLEY; SULFOBROMOPHTHALEIN;

EID: 0141518435     PISSN: 00338419     EISSN: None     Source Type: Journal    
DOI: 10.1148/radiol.2291020726     Document Type: Article

References (33)

1. Macdonald GA, Peduto AJ. Magnetic resonance imaging (MRI) and diseases of the liver and biliary tract. I. Basic principles, MRI in the assessment of diffuse and focal hepatic disease. J Gastroenterol Hepatol 2000; 15:980-991.
2. Semelka RC, Helmberger TKG. Contrast agents for MR imaging of the liver. Radiology 2001; 218:27-38.
3. Seneterre E, Taourel P, Bouvier Y, et al. Detection of hepatic metastases: ferumoxides enhanced MR imaging versus unenhanced MR imaging and CT during arterial portography. Radiology 1996; 200:785-792.
4. Scott J, Ward J, Guthrie JA, Wilson D, Robinson PJ. MRI of liver: a comparison of CNR enhancement using high dose and low dose ferumoxide infusion in patients with colorectal liver metastases. Magn Reson Imaging 2000; 18:297-303.
5. Petersein J, Spinazzi A, Giovagnoni A, et al. Focal liver lesions: evaluation of the efficacy of gadobenate dimeglumine in MR imaging-a multicenter phase III clinical study. Radiology 2000; 215:727-736.
6. Grazioli L, Morana G, Federle MP, et al. Focal nodular hyperplasia: morphologic and functional information from MR imaging with gadobenate dimeglumine. Radiology 2001; 221:731-739.
7. Weinmann HJ, Laniado M, Mützel W. Pharmacokinetics of GdDTPA/dimeglumine after intravenous injection into healthy volunteers. Physiol Chem Physics Med NMR 1984; 16:167-172.
8. de Haën C, La Ferla R, Maggioni F. Gadobenate dimeglumine 0.5 M solution for injection (MultiHance) as contrast agent for magnetic resonance imaging of the liver: mechanistic studies in animals. J Comput Assist Tomogr 1999; 23:S169-S179.
9. Cavagna FM, Maggioni F, Castelli PM, et al. Gadolinium chelates with weak binding to serum proteins: a new class of high-efficiency, general purpose contrast agents for magnetic resonance imaging. Invest Radiol 1997; 32:780-796.
10. Lorusso V, Arbughi T, Tirone P, de Haën C. Pharmacokinetics and tissue distribution in animals of gadobenate ion, the magnetic resonance imaging contrast enhancing component of gadobenate dimeglumine 0.5 M solution for injection (MultiHance). J Comput Assist Tomogr 1999; 23:S181-S194.
11. de Haën C, Lorusso V, Luzzani F, Tirone P. Hepatic transport of the magnetic resonance imaging contrast agent gadobenate dimeglumine in the rat. Acad Radiol 1995; 2:232-238.
12. de Haën C, Lorusso V, Tirone P. Hepatic transport of gadobenate dimeglumine in TR-rats. Acad Radiol 1996; 3:S454-S454.
13. Spinazzi A, Lorusso V, Pirovano G, Taroni P, Kirchin M, Davies A. MultiHance clinical pharmacology: biodistribution and MR enhancement of the liver. Acad Radiol 1998; 5:S86-S89.
14. Pascolo L, Cupelli F, Anelli PL, et al. Molecular mechanism for the hepatic uptake of magnetic resonance imaging contrast agents. Biochem Biophys Res Commun 1999; 257:746-752.
15. Pastor CM, Wiliams D, Yoneyama T, et al. Competition for tetrahydrobiopterin between phenylalanine hydroxylase and nitric oxide synthase in rat liver. J Biol Chem 1996; 271:24534-24538.
16. Hamilton RL, Berry MN, Williams MC, Severinghaus EM. A simple and inexpensive membrane "lung" for small organ perfusion. J Lipid Res 1974; 15:182-186.
17. Fossheim SL, Colet JM, Mansson S, Fahlvik AK, Muller RN, Klaveness J. Paramagnetic liposomes as magnetic resonance imaging contrast agents: assessment of contrast efficacy in various liver models. Invest Radiol 1998; 33:810-821.
18. Colet JM, Piérart C, Seghi F, Gabric I, Muller RN. Intravascular and intracellular hepatic relaxivities of superparamagnetic particles: an isolated and perfused organ pharmacokinetics study. J Magn Reson 1998; 134:199-205.
19. Fichtlscherer B, Mulsch A. MR imaging of nitrosyl-iron complexes: experimental study in rats. Radiology 2000; 216:225-231.
20. Pavone P, Patrizio G, Buoni C, et al. Comparison of Gd-BOPTA with Gd-DTPA in MR imaging of rat liver. Radiology 1990; 176:61-64.
21. Weinmann HJ, Bauer H, Frenzel T, Mühler A, Ebert W. Mechanism of hepatic uptake of gadoxetate disodium. Acad Radiol 1996; 3:S232-S234.
22. Marzola P, Maggioni F, Vicinanza E, Daprà M, Cavagna FM. Evaluation of the hepatocyte-specific contrast agent gadobenate dimeglumine for MR imaging of acute pancreatitis in a rat model. J Magn Reson Imaging 1997; 7:147-152.
23. Hagenbuch N, Reichel C, Stieger B, et al. Effect of phenobarbital on the expression of bile salt and organic anion transporters of rat liver. J Hepatol 2001; 34:881-887.
24. van Montfoort JE, Stieger B, Meijer DKF, Weinmann HJ, Meier PJ, Fattinger KE. Hepatic uptake of the magnetic resonance imaging contrast agent gadoxetate by organic anion transporting polypeptide Oatp1. J Pharmacol Exp Ther 1999; 290:153-157.
25. Pascolo L, Petrovic S, Cupelli F, et al. ABC protein transport of MRI contrast agents in canalicular rat liver plasma vesicles and yeast vacuoles. Biochem Biophys Res Commun 2001; 282:60-66.
26. Reichel C, Gao B, Van Montfoort J, et al. Localization and function of the organic anion transporting polypeptide Oatp2 in rat liver. Gastroenterology 1999; 117:688-695.
27. Cattori V, van Montfoort JE, Stieger B, et al. Localization of organic anion transporting polypeptide 4 (Oatp4) in rat liver and comparison of its substrate specificity with Oatp1, Oatp2 and Oatp3. Eur J Physiol 2001; 443:188-195.
28. Benness G, Khangure M, Morris I, et al. Hepatic kinetics and magnetic resonance imaging of gadolinium-EOB-DTPA in dogs. Invest Radiol 1996; 31:211-217.
29. 153gadolinium-EOB-DTPA scintigraphy in rats. Invest Radiol 1996; 31:154-160.
30. Hagenbuch B, Adler ID, Schmid TE. Molecular cloning and functional characterization of the mouse organic-anion-transporting polypeptide 1 (Oatp1) and mapping of the gene to chromosome X. Biochem J 2000; 345:115-120.
31. Lee J, Azzaroli F, Wang L, et al. Adaptive regulation of bile salt transporters in kidney and liver in obstructive cholestasis in the rat. Gastroenterology 2001; 121:1473-1484.
32. Scheffer GL, Kool M, de Haas M, et al. Tissue distribution and induction of human multidrug resistant protein 3. Lab Invest 2002; 82:193-201.
33. Kullak-Ublick GA, Ismair MG, Stieger B, et al. Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology 2001; 120:525-533.